8-K: Lyell Immunopharma Reports Third Quarter 2024 Financial Results and Business Highlights, Bolstering Pipeline with ImmPACT Bio Acquisition

Lyell Immunopharma announced its third quarter 2024 financial results, highlighting the acquisition of ImmPACT Bio and progress in its clinical pipeline, including the advancement of IMPT-314 and LYL119.

Summary

• Lyell Immunopharma reported a net loss of $44.6 million for the third quarter ended September 30, 2024, compared to a net loss of $50.9 million for the same period in 2023.
• Non-GAAP net loss for the quarter was $37.1 million, compared to $43.0 million in the same period of 2023.
• Research and development expenses were $39.5 million for the third quarter of 2024, down from $43.8 million in 2023.
• General and administrative expenses decreased to $11.8 million in the third quarter of 2024, compared to $15.5 million in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $460.7 million as of September 30, 2024, which is expected to fund operations into 2027.
• Lyell acquired ImmPACT Bio, adding IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate, to its pipeline.
• The company plans to present initial data from the Phase 1 trial of IMPT-314 at the American Society of Hematology (ASH) Annual Meeting in December 2024 and initiate a pivotal trial in 2025.
• Lyell is also progressing with the Phase 1 trial of LYL119, a next-generation ROR1-targeted CAR T-cell product candidate, with initial clinical data expected in the second half of 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the acquisition of ImmPACT Bio, progress in clinical trials, and a strong cash position. However, the company is still incurring losses and faces risks associated with clinical development and regulatory approvals.

Positives

• The acquisition of ImmPACT Bio has significantly enhanced Lyell's clinical pipeline.
• IMPT-314 has demonstrated promising Phase 1 clinical data, suggesting potential for improved response rates and durability in treating aggressive B-cell non-Hodgkins lymphoma.
• The company's strong cash position of $460.7 million provides a runway into 2027, supporting the advancement of its pipeline.
• Lyell is actively progressing with the clinical development of both IMPT-314 and LYL119.
• The decrease in both GAAP and non-GAAP net loss, R&D expenses, and G&A expenses compared to the same period in 2023 indicates improved cost management.

Negatives

• Lyell reported a net loss of $44.6 million for the third quarter of 2024.
• The company's cash reserves decreased from $562.7 million at the end of 2023 to $460.7 million as of September 30, 2024.
• The company is still in the clinical stage and has not yet achieved profitability.

Risks

• The company faces risks related to the successful integration of ImmPACT Bio and the manufacturing of IMPT-314.
• There are risks associated with the clinical development of IMPT-314 and LYL119, including the potential for adverse events and the uncertainty of regulatory approvals.
• The company's ability to achieve its goals is dependent on the sufficiency of its capital resources and may require additional funding.
• Macroeconomic conditions and geopolitical instability could impact the company's operations and financial performance.
• The nonclinical profiles of Lyell's product candidates may not translate into successful clinical trials.

Future Outlook

Lyell expects its cash reserves to fund operations into 2027 and plans to advance its pipeline through multiple clinical milestones, including initiating a pivotal trial for IMPT-314 in 2025 and obtaining initial clinical data for LYL119 in the second half of 2025.

Management Comments

• With our acquisition of ImmPACT now complete, we plan to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate we believe has the potential to deliver increased complete response rates with longer duration of response over approved CD19 CAR T-cell therapies for patients with aggressive Bcell nonHodgkins lymphoma, said Lynn Seely, M.D., Lyells President and CEO.
• We look forward to presenting the initial data from the Phase 1 trial of IMPT-314 at ASH next month and expect to initiate a pivotal clinical trial in 2025.
• Our strong cash position enables us to advance our pipeline through important clinical milestones and fund operations into 2027.

Industry Context

This announcement reflects the ongoing trend in the biotechnology industry towards developing next-generation CAR T-cell therapies with enhanced efficacy and durability. The acquisition of ImmPACT Bio and the advancement of IMPT-314 position Lyell as a key player in the competitive landscape of cell-based cancer treatments.

Comparison to Industry Standards

• Lyell's focus on developing dual-targeting CAR T-cell therapies like IMPT-314 aligns with the industry's push for more effective treatments for relapsed/refractory lymphomas, where single-target therapies have shown limitations.
• The company's approach to enhancing T-cell persistence and reducing exhaustion with technologies in LYL119 is consistent with the industry's efforts to improve the long-term efficacy of CAR T-cell therapies, addressing a key challenge in the field.
• Lyell's cash runway into 2027 is a positive sign, as many biotech companies face funding challenges, and this provides a competitive advantage.
• Companies like Gilead (Kite Pharma) and Novartis are leaders in the CAR T-cell space, and Lyell's progress with IMPT-314 and LYL119 will be closely watched as they move through clinical trials.

Stakeholder Impact

• Shareholders may view the acquisition of ImmPACT Bio and the progress in clinical trials positively.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Patients with solid tumors or hematologic malignancies may benefit from the development of new CAR T-cell therapies.
• Creditors and suppliers may be reassured by the company's strong cash position.

Next Steps

• Lyell will present initial data from the Phase 1 trial of IMPT-314 at the ASH 2024 Annual Meeting on December 9, 2024.
• The company plans to initiate a pivotal trial for IMPT-314 in 2025.
• Lyell will continue to progress with the Phase 1 trial of LYL119, with initial clinical data expected in the second half of 2025.

Key Dates

Keywords

CAR T-cell therapy, Immunotherapy, Oncology, Clinical trials, Biotechnology, Hematologic malignancies, Solid tumors, IMPT-314, LYL119, Acquisition, Financial results